German Validation Study of the Subjective Cognitive Decline Questionnaire (SCD-Q)

Last updated: November 27, 2024
Sponsor: Ludwig-Maximilians - University of Munich
Overall Status: Active - Recruiting

Phase

N/A

Condition

Memory Loss

Mental Disability

Dementia

Treatment

biomarkers

Cognitive Failure Questionnaire (CFQ)

Subjective Cognitive Decline-Questionnaire (SCD-Q)

Clinical Study ID

NCT06711952
22-1117
  • Ages > 50
  • All Genders
  • Accepts Healthy Volunteers

Study Summary

The SCD-Q (Subjective Cognitive Decline-Questionnaire) is an established instrument to quantify self-perceived cognitive decline. Both self- and informant-rated versions of the SCD-Q are available. However, the SCD-Q has not been validated in the German language yet. Hence, the investigators aim to validate the self-reported SCD-Q in a clinical sample in Germany.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Medical appointment for dementia diagnostics at the Alzheimer Therapie- undForschungszentrum

  • Provision of signed, written and dated informed consent

  • Capacity to give informed consent

Exclusion

Exclusion Criteria:

  • dementia in a very advance stage

  • Illiteracy

Study Design

Total Participants: 300
Treatment Group(s): 4
Primary Treatment: biomarkers
Phase:
Study Start date:
February 01, 2023
Estimated Completion Date:
March 31, 2025

Study Description

The SCD-Q is a well-established screening instrument to quantify perceived subjective cognitive decline. In addition to self-perceived cognitive complaints, a 24-item questionnaire for informants is part of the SCD-Q. It demonstrates high sensitivity and lower specificity for detecting dementia and early cognitive changes associated with dementia. However, the questionnaire has not been translated into German or validated. Plasma biomarkers for amyloid and tau pathology, as well as for neurodegeneration and astrocytic activation, have been developed and show promising sensitivity and specificity for detecting Alzheimer's disease (AD). A relevant proportion of biomarker-positive patients does not convert to mild cognitive impairment or Alzheimer's disease dementia during the disease course. Currently, the predictive value of blood biomarkers remains to be clarified, particularly in conjunction with SCD. This study aims to validate the SCD-Q in German and analyze possible connections with biomarkers and (digital) cognitive tests. Follow-up visits are planned.

Connect with a study center

  • Klinik und Poliklinik für Psychiatrie und Psychotherapie des LMU Klinikums

    München, Bayern 80336
    Germany

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.